Quality Level
assay
≥98% (HPLC)
form
powder
color
white to dark gray
solubility
1 M NaOH: 2 mg/mL, clear
storage temp.
-10 to -25°C
Application
LY341495 is suitable for use as a metabotropic glutamate receptor antagonist to study the role of glutamate signaling in various physiological and pathological processes. It is used in neurobiology studies, particularly in understanding the mechanisms underlying synaptic transmission/ neurotransmitter release , synaptic plasticity and neuronal excitability.
Biochem/physiol Actions
Potent antagonist against group II metabotropic glutamate receptors mGluR2 and mGluR3. LY341495 (LY 341495,LY-341,495, LY-341495) is a group II metabotropic glutamate receptor antagonist that potently reverses 3 μM mGluR agonist ACPD-dependent inhibition of forskolin-induced cAMP production in cells expressing either human mGluR2 ormGluR3 (IC50 = 21 nM and 14 nM, respectively), being much less potent against mGluR8, mGluR7, mGluR1a, mGluR5a, and mGluR4 (IC50 = 0.17, 0.99, 7.8, 8.2, 22μM, respectively). LY341495 is widely used for studying mGluR2/3-dependent cellular and physiological functions both in cultures in vitro and in animals in vivo (1-10 mg/kg via i.p. or s.c.).
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Fabiola M Ribeiro et al.
Pharmacological research, 115, 179-191 (2016-11-23)
Glutamate is the most important excitatory neurotransmitter of the mammalian central nervous system (CNS), playing an important role in memory, synaptic plasticity and neuronal development. However, glutamate overstimulation is also implicated in neuronal cell death. There are two major types
J M Witkin et al.
The Journal of pharmacology and experimental therapeutics, 358(1), 71-82 (2016-05-18)
Ketamine is a rapidly acting antidepressant in patients with treatment-resistant depression (TRD). Although the mechanisms underlying these effects are not fully established, inquiry to date has focused on the triggering of synaptogenesis transduction pathways via glutamatergic mechanisms. Preclinical data suggest
M L H J Hermes et al.
The Journal of pharmacology and experimental therapeutics, 336(3), 840-849 (2010-12-09)
Drugs that interact with group II metabotropic glutamate receptors (mGluRs) are presently being evaluated for a role in the treatment of anxiety disorders and symptoms of schizophrenia. Their mechanism of action is believed to involve a reduction in excitatory neurotransmission
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML4148-5MG | 04065272601542 |